Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes ( ) of patients continuing past 24 weeks ...)

HOME >> MEDICINE >> TECHNOLOGY

Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

) of patients continuing past 24 weeks in this study achieved the ADA target A1C goal of less than seven percent on JANUVIA 50 mg/metformin 1000 mg twice daily (n=153) compared to 44 percent on metformin 1000 mg twice daily alone (n=134). Further, 48 percent of patients treated with JANUVIA 50 mg/metformin 500 mg twice daily (n=147), 25 percent of patients treated with metformin 500 mg twice daily (n=117), and 23 percent of patients treated with JANUVIA 100 mg once daily (n=106) reached the ADA target A1C goal.

Duration of response was demonstrated by data showing that 85 percent of patients treated with JANUVIA 50 mg/metformin 1000 mg twice daily and 70 percent of patients treated with JANUVIA 100 mg once daily who achieved the target A1C goal of less than seven percent at Week 24 had a Week 54 A1C value of less than seven percent (n=96 and 33, respectively). In addition, 80 percent of patients treated with JANUVIA 50 mg/metformin 500 mg twice daily (n=65), 79 percent of patients treated with metformin 1000 mg twice daily (n=63), and 59 percent of patients treated with metformin 500 mg twice daily (n=34) who reached a goal A1C of less than seven percent at Week 24 had a Week 54 A1C value of less than seven percent.

Over the 54 week study, five out of 182 patients (three percent) treated with JANUVIA 50 mg/metformin 1000 mg twice daily and two out of 182 patients (one percent) treated with metformin 1000 mg twice daily had at least one episode of hypoglycemia. Incidences of gastrointestinal adverse experiences were similar to those observed with metformin alone (26 percent vs. 31 percent with metformin 1000 mg twice daily).

"Initial therapy with one agent is often unsuccessful at getting patients to blood sugar goals. Many patients may require initial combination therapy, and this study provides important and useful information about the use of sitagliptin and metformin, in addition to diet and exercise, in order to achieve and maintain blood su
'"/>

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting

Post Your Comments:

( ) of patients continuing past 24 weeks ...)Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes,Health